<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799327</url>
  </required_header>
  <id_info>
    <org_study_id>SHR20004-202</org_study_id>
    <nct_id>NCT04799327</nct_id>
  </id_info>
  <brief_title>The Effect of SHR20004（Noiiglutide ） on Body Weight in Obese Subjects Without Diabetes</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled，Parallel-group Clinical Trial to Assess the Efficacy and Safety of Noiiglutide Injection in Obese Subjects Without Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to assess the efficacy and safety of SHR20004 on body weight in&#xD;
      obese subjects without diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">May 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assign to SHR20004 or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in body weight in kilograms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative change from baseline in body weight(%)</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Relative change from baseline in body weight(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with body weight reduction greater than or equal to 5% and10% from baseline</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Proportion of subjects with body weight reduction greater than or equal to 5% and10% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in fasting plasma glucose in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting insulin</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in fasting insulin in μU/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting C-peptide</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in fasting C-peptide in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting blood lipids</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in fasting blood lipids including TC\TG\H-DLC\L-DLC in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycosylated hemoglobin</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in glycosylated hemoglobin(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist circumference</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in waist circumference in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist-to-hip ratio</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline waist-to-hip ratio（waist and hip will be combined to report waist-to-hip ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BMI</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in BMI (weight and height will be combined to report BMI in kg/m^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma glucose of 120 minutes after oral glucose tolerance test （OGTT）</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in plasma glucose of 120 minutes after OGTT in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin of 120 minutes after oral glucose tolerance test （OGTT）</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in insulin of 120 minutes after OGTT in μU/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-peptide of 120 minutes after oral glucose tolerance test （OGTT）</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in C-peptide of 120 minutes after OGTT in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in AUC0-2h of plasma glucose during OGTT</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in AUC0-2h of plasma glucose during OGTT in mmol*hr/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in AUC0-2h of insulin during OGTT</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in AUC0-2h of insulin during OGTT in μU*hr/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in AUC0-2h of C peptide during OGTT</measure>
    <time_frame>Week 0, Week 24</time_frame>
    <description>Change from baseline in AUC0-2h of C peptide during OGTT in ng*hr/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects developing anti-drug antibody of SHR20004</measure>
    <time_frame>Week 0-25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with an Adverse events</measure>
    <time_frame>Week 0-25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Injection site reactions</measure>
    <time_frame>Week 0-25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>Week 0-25</time_frame>
    <description>12-lead ECG in heart rate（beats）, PR interval（ms）, QT interval(ms), QTC interval(ms), and overall conclusion description</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of SHR20004 in plasma at steady state</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR20004</intervention_name>
    <description>SHR20004：low dose</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR20004</intervention_name>
    <description>SHR20004: medium dose</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR20004</intervention_name>
    <description>SHR20004: high dose</description>
    <arm_group_label>Treatment group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Treatment group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent obtained prior to any trial-related activities&#xD;
&#xD;
          2. Body mass index (BMI) between 28 and 40 kg/m2(both inclusive)&#xD;
&#xD;
          3. Diet and exercise management for at least 3 months before screening and less than 5%&#xD;
             change in body weight during the previous 3 months（self-reported）.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of endocrine disease or treatment that may significantly affect body weight&#xD;
             prior to screening visit&#xD;
&#xD;
          2. History of diabetes&#xD;
&#xD;
          3. Personal or family history of medullary thyroid carcinoma or multiple endocrine&#xD;
             neoplasia type 2 (MEN2)&#xD;
&#xD;
          4. History of pancreatitis&#xD;
&#xD;
          5. Previous surgical treatment of obesity&#xD;
&#xD;
          6. Screening calcitonin of 20 ng/L or above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial People's Hospital</name>
      <address>
        <city>TaiYuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

